

Day 1

Thursday, September 23

Sendai International Center

MS : Morning Seminar
LS : Luncheon Seminar
ES : Evening Seminar

IS : Industry Session
OS : Oral Session
E : Lectures in English

8 : 00 9 : 00 10 : 00 11 : 00 12 : 00 13 : 00 14 : 00 15 : 00 16 : 00 17 : 00 18 : 00 19 : 00

| | | | | | | | | | | | | |
|-----------------|--|---|--|---|--|----------------------|--|--|---|--|------------------------------------|--|
| Conference Bldg | No.1 (Main Hall 2F) | Presidential Symposium The Path from Stem Cells to Red Blood Cells Chairs : Hideo Harigae, Takahiro Suzuki | | Special Lecture 1 Chair : Koichi Akashi Speaker : David Scadden | LS1-1 Sanofi K.K. | Presidential Lecture | EHA Special Lecture Chair : Takanori Teshima Speaker : Elizabeth Macintyre | Symposium 3 Front Line of Genomic Analysis in Chronic Myeloid Leukemia Chairs : Naoto Takahashi, Tomoiku Takaku | | ES1-1 Bristol-Myers Squibb K.K. | Mini Concert (19 : 15~20 : 00) | |
| | No.2 (Tachibana 2F) | Symposium 1 Molecular Pathogenesis and Targeting Agents in AML Chairs : Seishi Ogawa, Fumihiko Ishikawa | | | LS1-2 ONO PHARMACEUTICAL CO., LTD. | | | Symposium 4 Recent Advances in the Field of Bone Marrow Failure Chairs : Hirohito Yamazaki, Atsushi Manabe | | ES1-2 Sumitomo Dainippon Pharma Co., Ltd. | JSH Business Meeting | |
| | No.3 (Hagi 2F) | Symposium 2 Molecular Mechanism of Inflammation and Tumor in Histiocytic Disorders Chairs : Yoko Shioda, Shouchi Ohga | | | LS1-3 AstraZeneca K.K. | | IS1-3 Alexion Pharma GK | Asian Joint Panel Discussion Virus-Associated Lymphoid Malignancies in Asian Countries Chairs : Kazuya Shimoda, Wen-Chien Chou | | ES1-3 Chugai Pharmaceutical Co., Ltd. | | |
| | No.4 (Sakura 1 2F) | OS1-4A | OS1-4B | | LS1-4 Chugai Pharmaceutical Co., Ltd. | | IS1-4 ONO PHARMACEUTICAL CO., LTD. | OS1-4C | OS1-4D | ES1-4 Pfizer Japan Inc. | | |
| | No.5 (Sakura 2 2F) | OS1-5A CML: Clinical Trial Chair : Eri Matsuki | OS1-5B CML: TKI Chair : Takaaki Ono | | LS1-5 Janssen Pharmaceutical K.K., Medical Affairs Division | | | OS1-5C Prognosis/Biomarkers in AML 1 Chair : Junko Takita | OS1-5D | ES1-5 ONO PHARMACEUTICAL CO., LTD. | | |
| | No.6 (Shirakashi 1 3F) | OS1-6A ALL, CLL: Clinical Chair : Katsuyoshi Koh | OS1-6B MDS: Basic Analysis Chair : Yuka Harada | | LS1-6 Novartis Pharma K.K. | | | OS1-6C Pathophysiology of MDS 3 Chair : Hideki Makishima | OS1-6D Pathophysiology of MDS 4 Chair : Ken Ishiyama | ES1-6 Takeda Pharmaceutical Company Limited | | |
| | No.7 (Shirakashi 2 3F) | OS1-7A | OS1-7B | | LS1-7 Sysmex Corporation | | | OS1-7C | OS1-7D Pediatric Hematology/Others Chair : Yuhki Koga | ES1-7 Eisai Co., Ltd. | | |
| Exhibition Bldg | No.8 (Exhibition Hall 3-A 1F) | SETP1 Pathophysiology and Novel Treatment of Acute Leukemia | | OS1-8 | LS1-8 Meiji Seika Pharma Co., Ltd. | | IS1-8 Asahi Kasei Pharma Corporation | Best Poster Awards 1 | | OS1-8D Pathophysiology of Multiple Myeloma Chair : Michiko Ichii | ES1-8 Nippon Shinyaku Co., Ltd. | |
| | No.9 (Exhibition Hall 3-B 1F) | SETP2 Novel Immunotherapy for Hematological Malignancies | | OS1-9B CAR-T Therapy and Carfilzomib Therapy Chair : Chikako Ohwada | LS1-9 Astellas Pharma Inc. | | | OS1-9C | OS1-9D | ES1-9 Janssen Pharmaceutical K.K. | | |
| | No.10 (Meeting Room 1 1F) | OS1-10A Cord Blood Transplantation Chair : Naoyuki Uchida | OS1-10B | | LS1-10 Kyowa Kirin Co., Ltd. | | | OS1-10C | OS1-10D | ES1-10 Sanofi K.K. | | |
| | No.11 (Meeting Room 2 1F) | OS1-11A | OS1-11B | | LS1-11 DAIICHI SANKYO COMPANY, LIMITED | | | OS1-11C | OS1-11D | ES1-11 Novartis Pharma K.K. | | |
| | No.12 (Meeting Room 3 1F) | OS1-12A | OS1-12B | | LS1-12 Otsuka Pharmaceutical Co., Ltd. | | | OS1-12C | OS1-12D | ES1-12 Alexion Pharma GK | | |
| | No.13A (Meeting Room 4-A 1F) | OS1-13A Hemophilia 1 Chair : Takeshi Matsumoto | OS1-13B | | LS1-13A Shionogi & Co., LTD | | | OS1-13C | OS1-13D | ES1-13A Takeda Pharmaceutical Company Limited | | |
| | No.13B (Meeting Room 4-B 1F) | | | | LS1-13B Bayer Yakuin, Ltd. | | | | | | | |
| | Exhibition (Exhibition Hall 1&2 1F) | Exhibition & Corporate Partner Lounge (9 : 00~17 : 00) | | | | | | | | | | |

8 : 00 9 : 00 10 : 00 11 : 00 12 : 00 13 : 00 14 : 00 15 : 00 16 : 00 17 : 00 18 : 00 19 : 00

| | 8 : 00 | 9 : 00 | 10 : 00 | 11 : 00 | 12 : 00 | 13 : 00 | 14 : 00 | 15 : 00 | 16 : 00 | 17 : 00 | 18 : 00 | 19 : 00 |
|-----------------|--|--|--|--|--|--|---|--|---------|---------|---------|---------|
| Conference Bldg | No.1 (Main Hall 2F) | | Symposium 5 Post CD19CAR-T Immune Cell Therapy Chairs : Naoki Hosen, Norimitsu Kadowaki | ASH Special Lecture Chair : Kinuko Mitani Speaker : Stephanie J. Lee | LS2-1 Takeda Pharmaceutical Company Limited | Plenary Session Chairs : Akifumi Takaori-Kondo, Hitoshi Kiyoi | Special Symposium | | | | | |
| | No.2 (Tachibana 2F) | MS2-2 Janssen Pharmaceutical K.K., Medical Affairs Division | Symposium 6 A Better Understanding of GVHD Biology on the Basis of the Intestinal Immunity Chairs : Koji Kato, Yoshihiro Inamoto | | LS2-2 Bristol-Myers Squibb K.K. | | JSH-EHA Joint Symposium (Symposium 8) New Phase of the Treatment of Intractable Lymphoma Chairs : Kenichi Ishizawa, Elizabeth Macintyre | | | | | |
| | No.3 (Hagi 2F) | MS2-3 Otsuka Pharmaceutical Co., Ltd. | Symposium 7 | OS2-3B Single Cell Analysis: Lymphoma Basic Research Chair : Junji Koya | LS2-3 Sumitomo Dainippon Pharma Co., Ltd. | | OS2-3C | OS2-3D NGS for Understanding AML Pathogenesis 2 Chair : Daichi Inoue | | | | |
| | No.4 (Sakura 1 2F) | MS2-4 Novartis Pharma K.K. | OS2-4A Multi-regional Clinical Trials in Multiple Myeloma Chair : Yasushi Takamatsu | OS2-4B Basic Research in Multiple Myeloma Chair : Naoya Mimura | LS2-4 Pfizer Japan Inc. | | OS2-4C CAR-T/ Gene-Modified T-Cell Therapy Chair : Seitaro Terakura | OS2-4D CAR-T Therapy: Clinical Chair : Hiroshi Fujiwara | | | | |
| | No.5 (Sakura 2 2F) | MS2-5 Eisai Co., Ltd. | OS2-5A Translational Research in AML 1 Chair : Ayana Kon | OS2-5B | LS2-5 AbbVie GK | | OS2-5C Novel Therapeutic Targets in AML Chair : Susumu Goyama | OS2-5D | | | | |
| | No.6 (Shirakashi 1 3F) | MS2-6 Sanofi K.K. | OS2-6A ALL: Basic 1 Chair : Masatoshi Takagi | OS2-6B ALL: Translational Research Chair : Yosuke Minami | LS2-6 PharmaEssentia Japan KK | | OS2-6C | OS2-6D | | | | |
| | No.7 (Shirakashi 2 3F) | MS2-7 Bristol-Myers Squibb K.K. | OS2-7A | OS2-7B | LS2-7 ZERIA Pharmaceutical Co., Ltd. | | OS2-7C Transcription and Epigenetic Regulation Chair : Goro Sashida | OS2-7D | | | | |
| Exhibition Bldg | No.8 (Exhibition Hall 3-A 1F) | MS2-8 Amgen K.K. Medical Affairs / Astellas Pharma Inc. | SETP3 Clinical and Basic Aspects of Multiple Myeloma | Best Poster Awards 2 | LS2-8 MSD K.K. | | OS2-8C | OS2-8D | | | | |
| | No.9 (Exhibition Hall 3-B 1F) | MS2-9 Sanofi K.K. | SETP4 Hematopoiesis and Hematopoietic Environment | OS2-9B | LS2-9 Symbio Pharmaceuticals Limited | | OS2-9C | OS2-9D | | | | |
| | No.10 (Meeting Room 1 1F) | MS2-10 CSL Behring K.K. | OS2-10A | OS2-10B | LS2-10 Zenyaku Kogyo Co., Ltd. | | OS2-10C | OS2-10D | | | | |
| | No.11 (Meeting Room 2 1F) | MS2-11 ONO PHARMACEUTICAL CO., LTD. | Women Doctors Career Symposium | | LS2-11 Alexion Pharma GK | | OS2-11C | OS2-11D | | | | |
| | No.12 (Meeting Room 3 1F) | MS2-12 DAIICHI SANKYO COMPANY, LIMITED | OS2-12A | OS2-12B | LS2-12 Fujimoto Pharmaceutical Group, Fujimoto Pharmaceutical Corporation | | OS2-12C | OS2-12D | | | | |
| | No.13A (Meeting Room 4-A 1F) | MS2-13A Nippon Shinyaku Co., Ltd. | OS2-13A Hemolytic Anemia Chair : Yasutaka Ueda | OS2-13B Erythropoiesis/ Other Red Blood Cell Disorders 1 Chair : Tatsuya Kawaguchi | LS2-13A Invivoscribe/LabPMM | | OS2-13C | OS2-13D | | | | |
| | No.13B (Meeting Room 4-B 1F) | | | | LS2-13B Asahi Kasei Pharma Corporation | | | | | | | |
| | Exhibition (Exhibition Hall 1&2 1F) | Exhibition & Corporate Partner Lounge (9 : 30~17 : 00) | | | | | | | | | | |

Day 3 Saturday, September 25 Sendai International Center

MS : Morning Seminar IS : Industry Session
 LS : Luncheon Seminar OS : Oral Session
 ES : Evening Seminar E : Lectures in English

| | 8 : 00 | 9 : 00 | 10 : 00 | 11 : 00 | 12 : 00 | 13 : 00 | 14 : 00 | 15 : 00 | 16 : 00 | 17 : 00 | 18 : 00 | 19 : 00 |
|-----------------|---|--|--|-------------------|--|---|-------------------------------------|--|-------------------|------------------|---------|---------|
| Conference Bldg | No.1 (Main Hall 2F) | MS3-1 Janssen Pharmaceutical K.K. | JSH-ASH Joint Symposium (Symposium 9) Recent Advance in the Immunotherapy for Multiple Myeloma Chairs : Junya Kuroda, Stephanie J. Lee | | Special Lecture 2 Chair : Hideo Harigae Speaker : Tomas Ganz | LS3-1 Novartis Pharma K.K. | Award Ceremony JSH Award Lecture | Symposium 10 Recent Progress in Hematopoietic Regulation Chairs : Yoshio Katayama, Hitoshi Takizawa | | Closing Ceremony | | |
| | No.2 (Tachibana 2F) | MS3-2 MSD K.K. | Clinical Debate 1 | Clinical Debate 2 | | LS3-2 Eisai Co., Ltd. | | Clinical Debate 3 | Clinical Debate 4 | | | |
| | No.3 (Hagi 2F) | MS3-3 AbbVie GK | OS3-3A | OS3-3B | | LS3-3 Sanofi K.K. | | Symposium 11 New Drug Modalities for the Treatment of Hemostatic and Thrombotic Disorders Chairs : Katsue Suzuki-Inoue, Tsukasa Ohmori | | | | |
| | No.4 (Sakura 1 2F) | MS3-4 Takeda Pharmaceutical Company Limited | OS3-4A | OS3-4B | | LS3-4 Janssen Pharmaceutical K.K. | | Public Symposium | | | | |
| | No.5 (Sakura 2 2F) | MS3-5 Kyowa Kirin Co., Ltd. | OS3-5A | OS3-5B | | LS3-5 Genmab K.K. | | OS3-5C Clinical Experiences in Treating FLT3-Mutated AML Chair : Yuichi Ishikawa | OS3-5D | | | |
| | No.6 (Shirakashi 1 3F) | MS3-6 Novartis Pharma K.K. | OS3-6A | OS3-6B | | LS3-6 Amgen K.K./ Astellas Pharma Inc. | | OS3-6C | OS3-6D | | | |
| | No.7 (Shirakashi 2 3F) | MS3-7 Pfizer Japan Inc. | OS3-7A | OS3-7B | | LS3-7 Alexion Pharma GK | | OS3-7C | OS3-7D | | | |
| Exhibition Bldg | No.8 (Exhibition Hall 3-A 1F) | MS3-8 CHUGAI PHARMACEUTICAL CO., LTD./ Nippon Shinyaku Co., Ltd. | Best Poster Awards 3 | | OS3-8B | LS3-8 Pfizer Japan Inc. | | OS3-8C | OS3-8D | | | |
| | No.9 (Exhibition Hall 3-B 1F) | MS3-9 Otsuka Pharmaceutical Co., Ltd. | OS3-9A | OS3-9B | | LS3-9 Bristol-Myers Squibb K.K. | | OS3-9C | OS3-9D | | | |
| | No.10 (Meeting Room 1 1F) | MS3-10 Bristol-Myers Squibb K.K. | OS3-10A | OS3-10B | | LS3-10 Nippon Shinyaku Co., Ltd. | | OS3-10C | OS3-10D | | | |
| | No.11 (Meeting Room 2 1F) | MS3-11 Sanofi K.K. | OS3-11A | OS3-11B | | LS3-11 CSL Behring K.K. | | OS3-11C | OS3-11D | | | |
| | No.12 (Meeting Room 3 1F) | MS3-12 Takeda Pharmaceutical Company Limited | OS3-12A | OS3-12B | | LS3-12 Takeda Pharmaceutical Company Limited | | OS3-12C | OS3-12D | | | |
| | No.13 (Meeting Room 4 1F) | MS3-13 Meiji Seika Pharma Co., Ltd. | OS3-13A | OS3-13B | | LS3-13 Mundipharma K.K. | | OS3-13C | OS3-13D | | | |
| | Exhibition (Exhibition Hall 1&2 1F) | Exhibition & Corporate Partner Lounge (9 : 30~16 : 00) | | | | | | | | | | |